Pomalidomide-Containing Regimens (PCR) for the Treatment of Relapsed and Refractory Multiple Myeloma

被引：0
|
作者：
Jimenez-Zepeda, Victor H. [1 ]
Venner, Christopher P. [2 ]
Belch, Andrew [3 ]
Sandhu, Irwindeep [4 ]
Nikitina, Tatiana [2 ]
Hewitt, Joanne D. [5 ]
Duggan, Peter [6 ]
Neri, Paola [7 ]
Rashid-Kolvear, Fariborz [8 ]
Bahlis, Nizar J. [7 ]
机构：
[1] Univ Calgary, Div Hematol, Calgary, AB, Canada
[2] Univ Alberta, Cross Canc Inst, Edmonton, AB, Canada
[3] Cross Canc Inst, Edmonton, AB T6G 1Z2, Canada
[4] Univ Alberta, Dept Med, Div Hematol, Edmonton, AB, Canada
[5] Cross Canc Inst, Nursing, Edmonton, AB T6G 1Z2, Canada
[6] Tom Baker Canc Clin, Dept Med Oncol & Hematol, Calgary, AB, Canada
[7] Univ Calgary, Southern Alberta Canc Res Inst, Calgary, AB, Canada
[8] Calgary Lab Serv, Calgary, AB, Canada
来源：
BLOOD | 2015年 / 126卷 / 23期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [41] THE EFFICACY OF BORTEZOMIB AND BORTEZOMIB-CONTAINING REGIMENS FOR TREATMENT OF RELAPSED/REFRACTORY MULTIPLE MYELOMA IN REAL CLINICAL PRACTICE
    Mitina, T.
    Golenkov, A.
    Kataeva, E.
    Lutskaya, T.
    Trifonova, E.
    Klinushkina, E.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 576 - 576
  • [42] Selinexor in Combination with Pomalidomide and Dexamethasone (SPd) for Treatment of Patients with Relapsed Refractory Multiple Myeloma (RRMM)
    Chen, Christine I.
    Bahlis, Nizar J.
    Gasparetto, Cristina
    Tuchman, Sascha A.
    Lipe, Brea
    Baljevic, Muhamed
    Kotb, Rami
    Sutherland, Heather J.
    Bensinger, William I.
    Sebag, Michael
    LeBlanc, Richard
    Venner, Christopher P.
    Schiller, Gary J.
    Lentzsch, Suzanne
    Callander, Natalie S.
    Rossi, Adriana C.
    Sheehan, Heidi
    Van Domelen, Dane
    Kazuharu, Kai
    Wang, Hongwei
    Shah, Jatin
    Shacham, Sharon
    Kauffman, Michael G.
    White, Darrell J.
    BLOOD, 2020, 136
  • [43] Pomalidomide alone or in combination with dexamethasone in Japanese patients with refractory or relapsed and refractory multiple myeloma
    Matsue, Kosei
    Iwasaki, Hiromi
    Chou, Takaaki
    Tobinai, Kensei
    Sunami, Kazutaka
    Ogawa, Yoshiaki
    Kurihara, Mari
    Midorikawa, Shuichi
    Zaki, Mohamed
    Doerr, Thomas
    Iida, Shinsuke
    CANCER SCIENCE, 2015, 106 (11): : 1561 - 1567
  • [44] Daratumumab, Pomalidomide, and Dexamethasone (DPd) for the Treatment of Relapsed/Refractory Multiple Myeloma: A Single Institution Experience
    Abdallah, Al-Ola
    Dunavin, Neil
    McClune, Brian
    Shune, Leyla
    Dias, Ajoy L.
    Mahmoudjafari, Zahra
    Hochard, Erica
    McGuirk, Joseph P.
    Ganguly, Siddhartha
    BLOOD, 2018, 132
  • [45] Treatment of relapsed or refractory multiple myeloma
    Maiolino, Angelo
    Garnica, Marcia
    LEUKEMIA RESEARCH, 2018, 73 : S3 - S3
  • [46] Treatment of Relapsed/Refractory Multiple Myeloma
    Kastritis, Efstathios
    Palumbo, Antonio
    Dimopoulos, Meletios A.
    SEMINARS IN HEMATOLOGY, 2009, 46 (02) : 143 - 157
  • [47] Treatment of relapsed and refractory multiple myeloma
    Engelhardt, M.
    Graziani, G.
    Javorniczky, R.
    Neubauer, J.
    Koehler, M.
    Herget, G. W.
    Waesch, R.
    ONKOLOGE, 2018, 24 (08): : 613 - 624
  • [48] Treatment of relapsed and refractory multiple myeloma
    Seema Singhal
    Jayesh Mehta
    Current Treatment Options in Oncology, 2003, 4 (3) : 229 - 237
  • [49] Treatment of relapsed and refractory multiple myeloma
    Sonneveld, Pieter
    Broijl, Annemiek
    HAEMATOLOGICA, 2016, 101 (04) : 396 - 406
  • [50] TREATMENT OF RELAPSED/REFRACTORY MULTIPLE MYELOMA
    Zamagni, E.
    Tacchetti, P.
    Barbato, S.
    Cavo, M.
    HAEMATOLOGICA, 2021, 106 (10) : 215 - 218
12345